1. WO/2017/076308 TCR FOR IDENTIFYING NY-ESO-1 ANTIGEN OLIGOPEPTIDE
WO
11.05.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/104453
GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD
LI, Yi
C07K 14/725
Loading...
Provided is a T cell receptor (TCR) capable of specifically binding oligopeptide SLLMWITQC derived from NY-ESO-1 antigens. The antigen oligopeptide SLLMWITQC can form a compound with HLA A0201, and the compound is presented to a cell surface. Also provided are a nucleic acid molecule for coding the TCR and a carrier containing the nucleic acid molecule as well as a cell transducing the TCR.
2. 106581685 改善中药提取液喷雾干燥时粘壁的方法以及辅料组合物
CN
26.04.2017
A61K 47/36 Loading...
A61K 47/36
Loading...
102016001147250
广州市香雪制药股份有限公司
施之琪
A61K 47/36
Loading...
本发明涉及一种改善中药提取液喷雾干燥时粘壁的辅料组合物以及方法。该辅料组合物由以下重量份的组分组成：麦芽糊精5‑30份、微粉硅胶1‑10份、微晶纤维素0‑5份。本发明的改善或避免中药提取液在喷雾干燥过程中粉料粘壁的方法包括以下步骤：将所述辅料组合物加入到中药浓缩液中，再进行喷雾干燥；麦芽糊精、微粉硅胶、微晶纤维素的加入量分别为所述中药浓缩液烘干后总重量的5％～30％、1％～10％、0‑5％。本发明的辅料组合物以及改善方法能够显著改善含糖量较高的巴戟天、枸杞子、熟地黄等中药提取液在喷雾干燥过程中的粘壁问题，所得喷雾干燥粉末流动性较好、不易吸潮，可压性好，干燥的粉末干压制粒一次成型率较高。
3. 206082588 一种用于超净工作台的多用途样品架
CN
12.04.2017
B01L 9/00 Loading...
B01L 9/00
Loading...
202016000587248
广州市香雪制药股份有限公司
钟时
B01L 9/00
Loading...
本实用新型公开了一种用于超净工作台的多用途样品架，所述多用途样品架包括一平台，所述平台上设置有接种棒摆放区、和试管摆放区，所述接种棒摆放区包括条形凹槽和支架，所述条形凹槽被设置用于容纳所述接种棒的棒体，所述支架为一U型凸台，所述支架位于所述条形凹槽的端部，所述试管摆放区包括第一凹槽组、第二凹槽组、和第三凹槽组，所述第一组凹槽组包括3至5个内径为12mm的凹槽；所述第二凹槽组包括3至5个内径为17mm的凹槽；所述第三凹槽包括3至5个内径为27mm的凹槽。可放置不同样品和多种实验器具，能够满足广泛的应用需求。
4. WO/2017/045323 LIQUID PACKAGING BOTTLE
WO
23.03.2017
B65D 23/00 Loading...
B65D 23/00
Loading...
PCT/CN2016/071017
GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD.
WANG, Yonghui
B65D 23/00
Loading...
A liquid packaging bottle, comprising a bottle body, a sucking tube, a first twist opening member and second twist opening member. The bottle body has an accommodation cavity for accommodating liquid. A first opening and second opening are provided on the bottle body. A dimension of the first opening is larger than that of the second opening. The first opening and second opening each communicate with the accommodation cavity. The sucking tube is disposed within the accommodation cavity and is connected to the accommodation cavity inner wall. One end of the sucking tube communicates with the first opening, and another end is disposed at the bottom of the accommodation cavity. The sucking tube is adhered to the accommodation cavity inner wall. The first twist opening member is connected to the bottle body and seals the first opening. When the first twist opening member separates from the bottle body, the first opening opens. The second twist opening member is connected to bottle body, and seals the second opening. When the second twist opening member separates from the bottle body, the second opening opens. The liquid packaging bottle thus maintains the seal of the liquid inside the bottle, and prevents external contaminants from entering the bottle.
5. WO/2017/045324 LIQUID PACKAGING BAG
WO
23.03.2017
B65D 30/10 Loading...
B65D 30/10
Loading...
PCT/CN2016/071018
GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD.
WANG, Yonghui
B65D 30/10
Loading...
A liquid packaging bag (10), comprising a bag body (100), a bag neck (200) and a grasping member (300). The bag body has a bottom portion and a top portion, and an accommodation cavity (110) for accommodating a liquid. The bag neck is connected to the top portion of the bag body. The bag neck is provided with a tube (210) for providing a liquid flow, the tube communicating with the accommodation cavity. The bag neck has a notch formed for tearing open the bag neck and opening an easy-tear hole of the tube. The grasping member is connected to the bag body. The liquid packaging bag is easily torn open and the liquid in the bag does not readily spill out.
6. 106519018 针对RHAMM抗原短肽的高亲和力T 细胞受体
CN
22.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
102015000570265
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种T细胞受体(TCR)，其具有结合ILSLELMKL‑HLA A0201复合物的特性；并且所述TCR对所述ILSLELMKL‑HLA A0201复合物的结合亲和力是野生型TCR对ILSLELMKL‑HLA A0201复合物的结合亲和力的至少2倍。本发明还提供了此类TCR与治疗剂的融合分子。此类TCR可以单独使用，也可与治疗剂联用，以靶向呈递ILSLELMKL‑HLA A0201复合物肿瘤细胞。
7. 106519019 识别PRAME抗原的TCR
CN
22.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201610957738.6
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自PRAME抗原的短肽GLSNLTHVL的T细胞受体(TCR)，所述抗原短肽GLSNLTHVL可与HLA A0201形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
8. WO/2017/041704 T CELL RECEPTOR HAVING HIGH AFFINITY TARGETING RHAMM ANTIGEN SHORT CHAIN POLYPEPTIDE
WO
16.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/098248
GUANGZHOU XIANGXUE PHARMACEUTICAL CO.LTD
LI, Yi
C07K 14/725
Loading...
Provided is a T cell receptor (TCR) having the characteristics of binding with the ILSLELMKL-HLA A0201 complex. The affinity of the TCR to bind with the ILSLELMKL-HLA A0201 complex is at least twice the affinity of a wild TCR to bind with the ILSLELMKL-HLA A0201 complex. Also provided is a fusion molecule for the TCR and a therapeutic agent. The TCR can be used independently or in combination with a therapeutic agent to targetedly present the ILSLELMKL-HLA A0201 complex to a tumor cell.
9. 106478808 识别NY-ESO-1抗原短肽的T细胞受体
CN
08.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
102015000741952
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自NY‑ESO‑1抗原的短肽LLMWITQCF的T细胞受体(TCR)，所述抗原短肽LLMWITQCF可与HLA A2402形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
10. 106478807 识别MAGE-A3 的T 细胞受体
CN
08.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
102015000734101
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自MAGE‑A3抗原的短肽SYVKVLHHM的T细胞受体(TCR)，所述抗原短肽SYVKVLHHM可与HLA A2402形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
11. 106478797 源自于SAGE1的肿瘤抗原短肽
CN
08.03.2017
C07K 14/47 Loading...
C07K 14/47
Loading...
102015000919825
广州市香雪制药股份有限公司
李懿
C07K 14/47
Loading...
本发明涉及新发现的源自于肿瘤抗原SAGE1的短肽，该短肽与MHC分子形成的复合物以及所述短肽与复合物的用途。同时，本发明还涉及与上述短肽或复合物结合的分子，以及这些分子的用途。
12. 106478809 识别PRAME抗原短肽的TCR
CN
08.03.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201610970100.6
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自PRAME抗原的短肽LYVDSLFFL的T细胞受体(TCR)，所述抗原短肽LYVDSLFFL可与HLA A2402形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
13. 106459178 针对RHAMM抗原短肽的高亲和力T细胞受体
CN
22.02.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201680001312.1
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种T细胞受体(TCR)，其具有结合ILSLELMKL‑HLA A0201复合物的特性；并且所述TCR对所述ILSLELMKL‑HLA A0201复合物的结合亲和力是野生型TCR对ILSLELMKL‑HLA A0201复合物的结合亲和力的至少2倍。本发明还提供了此类TCR与治疗剂的融合分子。此类TCR可以单独使用，也可与治疗剂联用，以靶向呈递ILSLELMKL‑HLA A0201复合物肿瘤细胞。
14. 106459177 高亲和力NY‑ESO T细胞受体
CN
22.02.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201680001303.2
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
提供了一种T细胞受体(TCR)及其与治疗剂的融合分子，所述TCR对SLLMWITQC‑HLA A2复合物的结合亲和力是野生型TCR的至少两倍，所述TCR可以单独使用，也可与治疗剂联用。
15. 106432475 高亲和力 NY‑ESO T 细胞受体
CN
22.02.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
102016000894646
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种T细胞受体(TCR)，其具有结合SLLMWITQC‑HLA A2复合物的特性；并且所述TCR对所述SLLMWITQC‑HLA A2复合物的结合亲和力是野生型TCR对SLLMWITQC‑HLA A2复合物的结合亲和力的至少10倍。本发明还提供了此类TCR与治疗剂的融合分子。此类TCR可以单独使用，也可与治疗剂联用，以靶向呈递SLLMWITQC‑HLA A2复合物肿瘤细胞。
16. 106459176 高亲和力 HCV T细胞受体
CN
22.02.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201580024400.9
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
提供了一种T细胞受体(TCR)，其结合KLVALGINAV‑HLA‑A2复合物且包含TCRα可变域和/或TCRβ可变域。还提供了所述TCR与治疗剂的融合体。所述TCR可以单独使用，也可与治疗剂联用，以靶向呈递KLVALGINAV‑HLA‑A2复合物的HCV感染细胞。
17. 106459179 识别RHAMM抗原短肽的T细胞受体
CN
22.02.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201680001317.4
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自RHAMM抗原短肽ILSLELMKL的T细胞受体(TCR)，所述抗原短肽ILSLELMKL可与HLA A0201形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
18. 106336457 识别MAGE-A3抗原短肽的T细胞受体
CN
18.01.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
201510733891.6
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自MAGE‑A3抗原的短肽SYVKVLHHM的T细胞受体(TCR)，所述抗原短肽SYVKVLHHM可与HLA A2402形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
19. 106279404 一种可溶且稳定的异质二聚TCR
CN
04.01.2017
C07K 14/725 Loading...
C07K 14/725
Loading...
102015000260322
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明公开了一种在其α链可变区与β链恒定区之间含有人工链间二硫键的异质二聚TCR，本发明的TCR可溶且稳定，能够被很好地复性、重折叠、纯化同时能够与其原配体特异性结合，而且本发明的T细胞受体具有较高的Tm值。本发明还公开了所述TCR的制备方法及用途。
20. WO/2016/184258 SOLUBLE AND STABLE HETERODIMERIC TCR
WO
24.11.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/077680
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
Disclosed are a heterodimeric TCR containing artificial interchain disulfide bond between the variable region of α chain and the constant region of βchain, a preparing method therefor and a use thereof.
21. WO/2016/177195 T CELL RECEPTOR FOR RECOGNIZING RHAMM ANTIGEN SHORT-CHAIN POLYPEPTIDE
WO
10.11.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/077679
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
Provided in the present invention is a T cell receptor (TCR) capable of binding specifically antigen short-chain polypeptide ILSLELMKL derived from RHAMM. The antigen short-chain polypeptide ILSLELMKL is capable of forming a complex with HLA A0201 and being presented together on the surface of a cell. Also provided in the present invention are a nucleic acid molecule encoding the TCR and a vector comprising the nucleic acid molecule. In addition, also provided in the present invention is a cell for transducing the TCR of the present invention.
22. WO/2016/177339 T CELL RECEPTOR FOR RECOGNIZING NY-ESO-1 ANTIGEN SHORT-CHAIN POLYPEPTIDE
WO
10.11.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/081180
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
Provided is a T cell receptor (TCR) capable of binding specifically antigen short-chain polypeptide SLLMWITQC derived from NY-ESO-1. The antigen short-chain polypeptide is capable of forming a complex with HLA A0201 and being presented together on the surface of a cell. Also provided are a nucleic acid molecule encoding the TCR and a vector comprising the nucleic acid molecule. In addition, the present invention also provides a cell for transducing the TCR of the present invention.
23. 106084036 识别PRAME抗原短肽的T细胞受体
CN
09.11.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
201510741810.7
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种能够特异性结合衍生自PRAME抗原的短肽RYLFPPLFM的T细胞受体(TCR)，所述抗原短肽RYLFPPLFM可与HLA A2402形成复合物并一起被呈递到细胞表面。本发明还提供了编码所述TCR的核酸分子以及包含所述核酸分子的载体。另外，本发明还提供了转导本发明TCR的细胞。
24. 105985427 高亲和力NY-ESO T细胞受体
CN
05.10.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
102015000067001
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种T细胞受体(TCR)，其具有结合SLLMWITQC‑HLA A2复合物的特性；并且所述TCR对所述SLLMWITQC‑HLA A2复合物的结合亲和力是野生型TCR对SLLMWITQC‑HLA A2复合物的结合亲和力的至少两倍。本发明还提供了此类TCR与治疗剂的融合分子。此类TCR可以单独使用，也可与治疗剂联用，以靶向呈递SLLMWITQC‑HLA A2复合物肿瘤细胞。
25. 105974014 知母的一测多评检测方法
CN
28.09.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
102016000294723
广州市香雪制药股份有限公司
张洪坤
G01N 30/02
Loading...
本发明涉及一种知母的一测多评检测方法，包括如下步骤：(1)取知母制备成供试品溶液；(2)取芒果苷配制成对照品溶液；(3)分别吸取所述供试品溶液和对照品溶液，注入高效液相色谱仪中进行测试，获取所述供试品溶液中芒果苷的保留时间和/或含量；(4)根据所述芒果苷的保留时间和/或含量，对所述供试品溶液中其余成分进行定性分析和/或定量分析。本发明以芒果苷作为对照品，构建了知母的一测多评检测方法，由此可以更好更全面的控制知母的质量，同时规避由多成含量测定带来的成本和操作问题，方法简单便于操作，且测定结果准确，方法重复性，耐用性好。
26. 104849375 橘红痰咳制剂的检测方法
CN
21.09.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
201510319380.X
广州市香雪制药股份有限公司
王艳慧
G01N 30/02
Loading...
本发明公开了一种橘红痰咳制剂的检测方法，包括橘红痰咳制剂的指纹图谱和多成分含量测定检测方法。所述HPLC指纹图谱检测方法包括如下步骤：(1)供试品溶液的配制：(2)测定：精密吸取供试品溶液，注入高效液相色谱仪中进行测定，得到橘红痰咳制剂的指纹图谱。本发明克服了现有质量标准中仅对其单一化学成分定量控制的片面性，能更有效地表征产品的内在质量，提供了一种全面评价橘红痰咳制剂的科学方法，进一步完善了其质量控制体系。
27. 105021751 玉屏风制剂中多种成分的含量测定方法
CN
07.09.2016
G01N 30/88 Loading...
G01N 30/88
Loading...
102015000377388
广州市香雪制药股份有限公司
周劲松
G01N 30/88
Loading...
本发明涉及一种玉屏风制剂中多种成分的含量测定方法，包括如下步骤：(1)取玉屏风制剂，粉碎或不粉碎后精密称定，加入甲醇回流提取1‑3h，过滤，浓缩后加甲醇定容，即得供试品溶液；(2)分别精密称取对照品升麻素苷、毛蕊异黄酮葡萄糖苷、升麻素、5‑O‑甲基维斯阿米醇苷、亥茅酚苷、毛蕊异黄酮、芒柄花素、白术内酯Ⅲ、白术内酯Ⅰ、白术内酯Ⅱ，加入甲醇溶解定容，即得混合对照品溶液；(3)测定：分别精密吸取供试品溶液和混合对照品溶液，注入高效液相色谱仪，以一定流动相条件梯度洗脱，采用多波长同时监测，即得。该方法可同时准确测定玉屏风制剂中10中成分的含量，能够客观、全面、灵敏地反映玉屏风制剂质量情况。
28. WO/2016/124142 HIGH AFFINITY NY-ESO T CELL RECEPTOR
WO
11.08.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2016/073389
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
Provided are a T cell receptor (TCR) and a molecule thereof fused with a therapeutic agent. The binding affinity of the TCR with respect to SLLMWITQC-HLA A2 complex is at least twice of that of a wild-type TCR. The TCR either can be used independently or can be used jointly with the therapeutic agent.
29. 105726723 化橘红饮片及其加工方法、应用
CN
06.07.2016
A61K 36/752 Loading...
A61K 36/752
Loading...
201610182590.3
广州市香雪制药股份有限公司
王艳慧
A61K 36/752
Loading...
本发明涉及一种化橘红饮片及其加工方法、应用，所述化橘红饮片的加工方法包括以下步骤：(1)拣选、分类、除杂；(2)清洗；(3)杀青切制(4)干燥。本发明加工方法缩短了生产加工周期，提高了生产效率，降低了生产成本，同时减少了药材中有效成分的损失，提高了质量稳定性，饮片外观更为美观、均匀。
30. 104432035 增强免疫力的保健营养组合物及其制备方法与应用
CN
22.06.2016



102014000686856
广州市香雪制药股份有限公司
黎校君


本发明公开了一种增强免疫力的保健营养组合物及其制备方法与应用，所述增强免疫力的保健营养组合物包括以下重量份的原料：发芽青稞粉20～40份，燕麦粉5～15份，乳粉10～30份，牦牛骨粉1～5份，苦荞麦5～15份，人参粉0.1～1份，低聚果糖2～8份，山药粉5～15份、金丝枣粉1～10份，雨生红球藻0.1～1份，罗汉果粉0.1～1份。本发明保健营养组合物能够根据现代消费者的需要，起到增强免疫力的功效，且原料天然，没有任何副作用，非常适合中老年人以及需要增强免疫力的人群使用，口感好，得到消费者的喜爱。
31. 105675751 抗病毒口服液的质量检测方法
CN
15.06.2016
G01N 30/02 Loading...
G01N 30/02
Loading...
201610032196.1
广州市香雪制药股份有限公司
孟鹤
G01N 30/02
Loading...
本发明属于医药领域，具体涉及一种抗病毒口服液的质量检测方法。其通过HPLC方法对所述口服液中(R,S)-告依春、芒果苷、连翘酯苷I、连翘酯苷H、连翘酯苷A、松脂酚-4-O-葡萄糖苷和连翘苷七个活性成分进行含量测定。所述检测方法稳定性好并且重现性佳。
32. 105683215 高稳定性的T细胞受体及其制法和应用
CN
15.06.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
201480036288.6
广州市香雪制药股份有限公司
李懿
C07K 14/725
Loading...
本发明提供了一种高稳定性的T细胞受体，所述T细胞受体在其疏水芯区域发生了突变，引起了其稳定性的提高。本发明还提供了所述T细胞受体的制备方法和应用。
33. WO/2016/070814 SOLUBLE HETERODIMERIC T CELL RECEPTOR, AND PREPARATION METHOD AND USE THEREOF
WO
12.05.2016
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2015/093806
GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD.
LI, Yi
C07K 14/725
Loading...
Provided is a high-stability T cell receptor (TCR). The TCR comprises (i) the whole or a part of TCRα chain except a transmembrane domain thereof, and (ii) the whole or a part of TCRβ chain except a transmembrane domain thereof, both the (i) and the (ii) comprising a functional variable domain and at least a part of a constant domain of a TCR chain. An artificial interchain disulfide bond links the constant domains of the TCRα and β chains, and a Tm value of the T cell receptor is greater than or equal to 45ºC.
34. 105548454 小儿化食中药制剂的质量检测方法
CN
04.05.2016
G01N 30/90 Loading...
G01N 30/90
Loading...
201610112717.4
广州市香雪制药股份有限公司
田庆龙
G01N 30/90
Loading...
本发明涉及一种小儿化食中药制剂的质量检测方法，所述小儿化食中药制剂，其有效成分主要由如下重量份的原料制备而成：山楂9-11份、麦芽9-11份、六神曲9-11份、大黄9-11份、牵牛子19-21份、槟榔9-11份、莪术4-6份、三棱4-6份，所述质量检测方法是采用薄层色谱法对所述山楂、莪术和三棱进行检测。该质量检测方法，通过合理控制检测条件，有效地对处方中的山楂、莪术和三棱进行了薄层鉴别，可在现行标准的基础上，进一步对处方中的君药和臣药进行鉴别，提高、完善了小儿化食中药制剂的质量标准，且该方法操作简便、灵敏度高、稳定性好，能够有效控制小儿化食中药制剂生产过程中的产品质量，保证产品疗效。
35. WO/2016/033727 MEDICINE FOR PREVENTING AND TREATING VASCULAR DISEASES AND PREPARATION METHOD THEREOF
WO
10.03.2016
A61K 31/704 Loading...
A61K 31/704
Loading...
PCT/CN2014/085684
XIANGXUE PHARMACEUTICAL CO., LTD.
WANG, Yiming
A61K 31/704
Loading...
Disclosed is a medicine for preventing and treating vascular diseases. The effective ingredients of the medicine are the functional ingredient group of ginsenoside and the functional ingredient group of salvianolic acid; wherein the weight ratio of the functional ingredient group of ginsenoside and the functional ingredient group of salvianolic acid is 1 : (0.1-20); and in the functional ingredient group of ginsenoside, the content of ginsenoside Rg1 by mass percentage is 6.0% - 10.0%, the content of ginsenoside Re by mass percentage is 5.0 - 6.0%, the content of ginsenoside Rb1 by mass percentage is 11% - 13%, and the sum of the contents of ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rc, ginsenoside Rb2 and ginsenoside Rd by mass percentage is 40 - 50%; and in the functional ingredient group of salvianolic acid, the content of salvianolic acid B by mass percentage is greater than or equal to 50.0%; the sum of the contents of total salvianolic acid is greater than or equal to 55.0%.
36. 205060279 液体包装瓶
CN
02.03.2016
B65D 23/00 Loading...
B65D 23/00
Loading...
201520723843.4
广州市香雪制药股份有限公司
王永辉
B65D 23/00
Loading...
本实用新型公开了一种液体包装瓶。该液体包装瓶包括瓶体、吸管、第一扭开部件及第二扭开部件。瓶体具有用于盛放液体的容置腔，瓶体上设有第一开口及第二开口，第一开口尺寸较第二开口尺寸大，第一开口及第二开口均连通于容置腔。吸管位于所述容置腔内，且吸管连接于容置腔的内壁，吸管的一端连通于第一开口，另一端位于容置腔的底部，吸管紧贴容置腔内壁。第一扭开部件连接于瓶体，且密封第一开口，当所述第一扭开部件与所述瓶体分离时，所述第一开口开启，第二扭开部件连接于瓶体，且密封第二开口，当所述第二扭开部件与所述瓶体分离时，所述第二开口开启。本实用新型的液体包装瓶，既保持了瓶内液体的密封性，又避免了瓶外的污染物进入瓶内。
37. 205060319 液体包装袋
CN
02.03.2016
B65D 30/10 Loading...
B65D 30/10
Loading...
201520723595.3
广州市香雪制药股份有限公司
王永辉
B65D 30/10
Loading...
本实用新型公开了一种液体包装袋。该液体包装袋包括袋体、袋颈及拿捏部件。所述袋体具有底部及顶部，所述袋体具有用于盛放液体的容置腔。所述袋颈连接在所述袋体的顶部，所述袋颈设置有用于供液体流淌的管道，所述管道连通于所述容置腔，所述袋颈具有缺口形成用于撕开所述袋颈并打开所述管道的易撕口。所述拿捏部件连接于所述袋体。本实用新型涉及的液体包装袋，易于撕开、袋内液体不易泼洒。
38. WO/2015/192757 HIGH-AFFINITY HCV T CELL RECEPTOR
WO
23.12.2015
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2015/081491
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
Provided is a T cell receptor(TCR), combining with KLVALGINAV-HLA-A 2 compound and comprising a TCR α variable domain and/or TCR β variable domain. Also provided is a fusion of a TCR and a therapeutic agent. The TCR can be used separately, and in combination with the therapeutic agent, for target presenting of HCV infection cells of a KLVALGINAV-HLA-A 2 compound.
39. 105130762 分离制备石菖蒲挥发性成分的方法
CN
09.12.2015
C07C 41/34 Loading...
C07C 41/34
Loading...
201510443241.8
广州市香雪制药股份有限公司
伍军
C07C 41/34
Loading...
本发明涉及一种分离制备石菖蒲挥发性成分的方法，所述石菖蒲挥发性成分为单体化合物或单体化合物的组合物，包括如下步骤：以石菖蒲为原料，提取得到石菖蒲挥发性成分粗提物；将所述石菖蒲挥发性成分粗提物用有机溶剂溶解，作为待分离制备的样品溶液；采用超临界流体色谱技术对所述样品溶液进行分离制备，得到石菖蒲挥发性成分。本发明通过超临界流体色谱技术实现了石菖蒲挥发性成分的分离制备，同时开辟了α-细辛醚、β-细辛醚和γ-细辛醚制备的新途径，利用超临界流体色谱技术，通过简单的进样分离操作即可同步获得高纯度的α-细辛醚、β-细辛醚和γ-细辛醚，且产品得率高，分离周期短，效率高。
40. 105129249 液体包装瓶
CN
09.12.2015
B65D 83/32 Loading...
B65D 83/32
Loading...
201510599337.3
广州市香雪制药股份有限公司
王永辉
B65D 83/32
Loading...
本发明公开了一种液体包装瓶。该液体包装瓶包括瓶体、吸管、第一扭开部件及第二扭开部件。瓶体具有用于盛放液体的容置腔，瓶体上设有第一开口及第二开口，第一开口及所述第二开口均连通于容置腔。吸管位于所述容置腔内，且吸管连接于容置腔的内壁，吸管的一端连通于第一开口，另一端位于容置腔的底部。第一扭开部件连接于瓶体，且密封第一开口，当所述第一扭开部件与所述瓶体分离时，所述第一开口开启，第二扭开部件连接于瓶体，且密封第二开口，当所述第二扭开部件与所述瓶体分离时，所述第二开口开启。本发明的液体包装瓶，既保持了瓶内液体的密封性，又避免了瓶外的污染物进入瓶内。
41. 105092761 抗病毒口服液挥发性成分的检测方法
CN
25.11.2015
G01N 30/88 Loading...
G01N 30/88
Loading...
201510516225.7
广州市香雪制药股份有限公司
孟鹤
G01N 30/88
Loading...
本发明涉及一种抗病毒口服液挥发性成分的检测方法，属于药物分析技术领域。该检测方法采用水蒸气蒸馏法，萃取法或有机溶剂回流提取法提取待测样品中的挥发性成分，制得样品溶液；并精密称取α-蒎烯、β-蒎烯、松油烯-4-醇、松油醇、龙脑、甲基丁香酚、百秋李醇、β-细辛醚、广藿香酮和α-细辛醚，以有机溶剂配制挥发性成分对照品溶液；再通过气相色谱同时测定上述10种挥发性成分，能够更为全面的反映药材信息，评价产品质量，提高了质量标准，同时也为产品的生产工艺优化提供了条件。
42. 105044260 玉屏风制剂指纹图谱的构建方法和检测方法
CN
11.11.2015
G01N 30/88 Loading...
G01N 30/88
Loading...
201510378950.2
广州市香雪制药股份有限公司
张洪坤
G01N 30/88
Loading...
本发明涉及一种玉屏风制剂指纹图谱的构建方法及检测方法。所述构建方法包括如下步骤：取玉屏风制剂，粉碎或不粉碎后精密称定，然后精密加入甲醇，回流提取1-3h，过滤，即得供试品溶液；精密吸取供试品溶液，注入高效液相色谱仪中进行测定，得到由22个共有特征峰构成的玉屏风制剂指纹图谱，其中，所述高效液相色谱仪采用的流动相为：以乙腈为流动相A，体积浓度0.02-0.1％磷酸水溶液为流动相B，采用梯度洗脱方式。该构建方法建立了由22个共有峰组成的玉屏风制剂液相色谱指纹图谱，共有峰具有特征性，可全面有效地控制玉屏风制剂的质量，同时鉴定了其中10个主要指纹峰，并对全部的共有峰进行了峰归属，结果可靠，重复性好。
43. 105021751 玉屏风制剂中多种成分的含量测定方法
CN
04.11.2015
G01N 30/88 Loading...
G01N 30/88
Loading...
201510377388.1
广州市香雪制药股份有限公司
周劲松
G01N 30/88
Loading...
本发明涉及一种玉屏风制剂中多种成分的含量测定方法，包括如下步骤：(1)取玉屏风制剂，粉碎或不粉碎后精密称定，加入甲醇回流提取1-3h，过滤，浓缩后加甲醇定容，即得供试品溶液；(2)分别精密称取对照品升麻素苷、毛蕊异黄酮葡萄糖苷、升麻素、5-O-甲基维斯阿米醇苷、亥茅酚苷、毛蕊异黄酮、芒柄花素、白术内酯Ⅲ、白术内酯Ⅰ、白术内酯Ⅱ，加入甲醇溶解定容，即得混合对照品溶液；(3)测定：分别精密吸取供试品溶液和混合对照品溶液，注入高效液相色谱仪，以一定流动相条件梯度洗脱，采用多波长同时监测，即得。该方法可同时准确测定玉屏风制剂中10中成分的含量，能够客观、全面、灵敏地反映玉屏风制剂质量情况。
44. 105018614 白芍品种检测方法
CN
04.11.2015
C12Q 1/68 Loading...
C12Q 1/68
Loading...
201510423176.2
广州市香雪制药股份有限公司
胡珊
C12Q 1/68
Loading...
本发明涉及一种白芍品种检测方法，属于植物品种鉴别技术领域。该方法包括以下步骤：建立鉴别模型：取不同品种的白芍，分别提取其DNA，然后将所提取到的DNA用引物进行聚合酶链式反应扩增，得到扩增产物，并对该扩增产物进行电泳分离，得到不同品种白芍的DNA电泳图，以该电泳图的谱图信息建立白芍品种鉴别模型；品种鉴别：取待测白芍，按照上述方法得到其DNA电泳图，将该待测白芍电泳图的谱图信息代入上述鉴别模型中进行分析，判定得到该白芍的品种。该方法为白芍品种的区分提供了有效可靠的鉴定手段。相对于传统形态鉴定具有巨大优势，在白芍药材的研究和应用中，为解决品种混乱和品种优劣问题提供了一种新的手段。
45. 104432037 抗氧化的保健营养组合物及其制备方法与应用
CN
25.03.2015
A23L 33/125 Loading...
A23L 33/125
Loading...
201410687455.5
广州市香雪制药股份有限公司
李小妹
A23L 33/125
Loading...
本发明公开了一种抗氧化的保健营养组合物及其制备方法与应用，包括以下重量份的原料：发芽青稞粉20～50份，燕麦粉5～15份，奶粉20～40份，牦牛骨粉1～5份，蛹虫草粉0.1～1.5份，针叶樱桃粉0.1～1份，雨生红球藻0.1～1份，低聚果糖2～10份，速溶咖啡粉1～10份或绿茶提取物2～10份或速溶红茶粉2～10份、白砂糖10～40份。本发明保健营养组合物能够根据现代消费者的需要，起到抗氧化的功效，且原料天然，没有任何副作用，口感好，深得消费者的喜爱。
46. 104432036 缓解视疲劳的保健营养组合物及其制备方法与应用
CN
25.03.2015
A23L 33/00 Loading...
A23L 33/00
Loading...
201410687071.3
广州市香雪制药股份有限公司
康志英
A23L 33/00
Loading...
本发明公开了一种缓解视疲劳的保健营养组合物及其制备方法与应用，包括以下重量份的原料：发芽青稞粉20～50份，燕麦粉5～20份，奶粉6～16份，牦牛骨粉1～5份，枸杞子粉1～5份，牛磺酸0.1～1份，叶黄素酯微囊粉0.1～1份，麦芽提取物8～15份，白砂糖25～55份，DHA微囊粉0.2～1份，低聚果糖2～8份、可可粉2～10份。本发明保健营养组合物能够根据现代消费者的需要，起到缓解视疲劳的功效，且原料天然，没有任何副作用，口感好，得到消费者的喜爱。
47. 104256600 Health care nutritional composition, preparation method and application thereof
CN
07.01.2015
A23L 33/105 Loading...
A23L 33/105
Loading...
201410522557.1
广州市香雪制药股份有限公司
李小妹
A23L 33/105
Loading...
The invention discloses a health care nutritional composition, a preparation method and application thereof, and the composition has effects of fatigue resistance and increase of hypoxia tolerance. The health care nutritional composition comprises effective constituents which are prepared from the following raw materials in parts by weight: 20-40 parts of maca, 15-40 parts of rhodiola rosea, 5-20 parts of American ginseng, 20-40 parts of the fruit of Chinese wolfberry, 20-40 parts of sealwort, and 5-10 parts of cinnamon. The health care nutritional composition disclosed by the invention is prepared form the purely natural raw materials such as maca, rhodiola rosea, American ginseng, the fruit of Chinese wolfberry, sealwort and cinnamon as the effective constituents; the raw materials are compatible; through experimental verification, the health care nutritional composition is good in anti-fatigue effect, excellent in increase of hypoxia tolerance and the like, and further is free of any side effect and good in mouth feeling.
48. WO/2014/206304 HIGH-STABILITY T-CELL RECEPTOR AND PREPARATION METHOD AND APPLICATION THEREOF
WO
31.12.2014
C07K 14/725 Loading...
C07K 14/725
Loading...
PCT/CN2014/080773
GUANGZHOU XIANGXUE PHARMACEUTICAL CO. LTD
LI, Yi
C07K 14/725
Loading...
The present invention provides a high-stability T-cell receptor, a hydrophobic core region of said T-cell receptor having undergone a mutation, leading to the increased stability thereof. The present invention additionally provides a preparation method and an application of the T-cell receptor.
49. 203989022 口服液专用PET瓶
CN
10.12.2014
A61J 1/05 Loading...
A61J 1/05
Loading...
201420334817.8
广州市香雪制药股份有限公司
王永辉
A61J 1/05
Loading...
本实用新型涉及一种口服液专用PET瓶，其包括PET瓶体、封口膜以及HDPE瓶盖。该口服液专用PET瓶的HDPE瓶盖在密封部的末端向内延伸形成环状内扣，且密封部的内周壁形状与瓶口的外周壁的形状一致，从而HDPE瓶盖可以扣合在瓶口上，密封性好。当使用者使用时，只需要简单的掀开HDPE瓶盖，并掀开封口膜直接饮用或者用吸管刺穿封口膜插入PET瓶体内饮用。本实用新型的口服液专用PET瓶结构简单，且操作简便、使用过程安全卫生。
50. 102125131 Instant green tea powder and preparation method thereof
CN
20.07.2011
A23F 3/16 Loading...
A23F 3/16
Loading...
201010585628.4
Guangzhou Xiangxue Pharmaceutical Co.,Ltd.
Kang Zhiying
A23F 3/16
Loading...
The invention relates to a preparation method of instant green tea powder, relating to a plant extract and a preparation method thereof in the field of foods. The instant green tea powder is prepared through processes, i.e. spreading, de-enzyming, water extraction, filtering, extract concentration and drying, by taking fresh green tea leaves as raw materials. Microwave de-enzyming and flash extraction are characterized in that the effective components of the green tea raw materials can be extracted within shorter time at lower temperature and the chlorophylls and the tea polyphenols of a product are ensured not to be damaged, thereby the extract appears in green and also the effective components and the aromatic substances of green tea are maintained to a greater degree; in addition, the steps of high-speed centrifugation, microfiltration and membrane concentration are all operated at normal temperature, therefore colors, nutrient components and aroma are beneficial to preservation, and the quality of the product is effectively enhanced.
51. 102100326 Compound Terminalia chebula Retz throat lozenge and preparation method thereof
CN
22.06.2011
A23L 1/09 Loading...
A23L 1/09
Loading...
201010585612.3
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Kang Zhiying
A23L 1/09
Loading...
The invention discloses a compound Terminalia chebula Retz throat lozenge and a preparation method thereof, and relates to a food containing plant extracts (particularly containing a Terminalia chebula Retz water extract and a green tea water extract) and a preparation method thereof. The throat lozenge is prepared from the following raw materials in percentage by mass: 4-12% of dried Terminalia chebula Retz water extract, 1-4% of dried green tea water extract, 7-12% of polyethylene glycol 6000, 0.5-1.5% of Arabic gum, 70-85% of sorbitol or erythritol or isomaltitol and 0.3-3% of sweetening agent. The preparation method comprises the following steps: proportioning the raw materials, mixing, pulverizing, carrying out secondary granulation, and tabletting. The compound Terminalia chebula Retz throat lozenge disclosed by the invention solves the problems of high oxidative stain tendency, coarse mouthfeel, acerb taste, poor stability, short shelf life and the like of the traditional Terminalia chebula Retz throat lozenge, and provides a throat lozenge, which has better effects of reducing fever, relieving the sore throat and promoting the production of the body fluid and has the advantages of excellent mouthfeel and high stability, for consumers.
52. 101972027 Natural plant beverage and preparation method thereof
CN
16.02.2011
A23L 2/38 Loading...
A23L 2/38
Loading...
201010292602.0
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Kang Zhiying
A23L 2/38
Loading...
The invention discloses a natural plant beverage and a preparation method thereof. The beverage comprises the following components in percentage by weight: 0.2 to 0.6 percent of mulberry leaves, 0.5 to 1.5 percent of chrysanthemum, 0.2 to 0.8 percent of fresh reed rhizome, 0.05 to 0.4 percent of platycodon root, 0.1 to 0.6 percent of licorice root and the balance of water and auxiliary materials. The beverage is prepared by extracting active ingredients from natural plants. The plant beverage provided by the invention has a unique flavor of the chrysanthemum and has sweet, cool and fresh smells, is a new beverage suitable for the taste experience of people. Moreover, in order to meet the requirements on the mouthfeel and the health of different groups of people, the beverage provided by the invention comprises two types, namely a sugar type and a sugar-free type, wherein the sugar-free type plant beverage is mainly developed aiming at increasingly large groups of diabetes patients.
53. 101972323 Quality analysis method for loins-strengthening and kidney-invigorating oral liquid
CN
16.02.2011
G01N 30/02 Loading...
G01N 30/02
Loading...
201010281930.0
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Lian Linsheng
G01N 30/02
Loading...
The invention discloses a quality analysis method for loins-strengthening and kidney-invigorating oral liquid. The content of formononetin is measured by high performance liquid chromatography (HPLC), and the method comprises the steps of: preparing test solution, preparing reference solution and measuring. The method controls quality of the loins-strengthening and kidney-invigorating oral liquid by measuring the content of formononetin in the loins-strengthening and kidney-invigorating oral liquid through the HPLC, has high sensitivity, high specificity, no interference on negative control, has the accuracy, repeatability, linear relation and stability which can meet the requirements of scientific research and production, can more effectively control the product quality, and ensures the curative effect of medicaments.
54. 101961405 Method for testing content of pinoresinol diglucoside in compound eucommia bark tablet
CN
02.02.2011
G01N 30/36 Loading...
G01N 30/36
Loading...
201010273815.9
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Cai Chunling
G01N 30/36
Loading...
The invention discloses a method for testing the content of pinoresinol diglucoside in a compound eucommia bark tablet, which belongs to a method of testing the content of an active ingredient of a medicament in the medicine field. Testing by high performance liquid chromatography, the content of the pinoresinol diglucoside in each compound eucommia bark tablet is not less than 0.05mg, the basic weight of each tablet is 0.35g, in particular octadecyl silane bonded silica is used as filler; methanol is used as a mobile phase A and water is used as a mobile phase B to carry out gradient elution; the detection wavelength is 230mum and the flow rate is 1ml/min; the theoretical plate number in the term of the pinoresinol diglucoside is not less than 2000; and20mul of reference substance solution and testing solution are respectively accurately sucked, and injected into a high performance liquid chromatograph, tested and calculated according to an external standard method to obtain the content of the pinoresinol diglucoside. The method for testing the content of the pinoresinol diglucoside has high sensitivity, and proved by an experiment, the accuracy, reproducibility, linearity, stability of the method are all meet the requirements.
55. 101961430 Quality analysis method of compound Ganmaoling tablets
CN
02.02.2011
G01N 30/02 Loading...
G01N 30/02
Loading...
201010281926.4
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Kang Zhiying
G01N 30/02
Loading...
The invention discloses a quality analysis method of compound Ganmaoling tablets. In the method, high-performance liquid chromatography (HLPC) is used for measure the chlorogenic acid content, acetaminophen content and caffeine content of the compound Ganmaoling tablets, test product solution is prepared and reference product solution is prepared and measured. The quality analysis method of the invention can detect the acetaminophen, chlorogenic acid and caffeine components under the same color spectrum condition at the same time, so the test time and cost are saved and the working efficiency is improved; the test method has high sensitivity, high separating degree; the basic line is stable; a negative reference is not affected; and the accuracy, repeatability, linearity and stability of the test method meet scientific research and production requirements, and the detection method is suitable for promotion and application.
56. 101953913 Quality analysis method of Zhongfenghuichun capsules
CN
26.01.2011
A61K 36/732 Loading...
A61K 36/732
Loading...
201010281928.3
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Li Xiaomei
A61K 36/732
Loading...
The invention discloses a quality analysis method of Zhongfenghuichun capsules. In the method, the solvent of the sample solution is prepared, the solvent is the solution of acetonitrile and 1% formic acid in a volume ratio of 40:60; and the chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as filler, the solution of acetonitrile and 1% formic acid in a volume ratio of 40:60 is used as the mobile phase, the detection wavelength is 286nm, the high performance liquid chromatography is used to measure the content of Salvianolic acid B in the Zhongfenghuichun capsules, and the theoretical plate number is calculated according to Salvianolic acid B chromatographic peaks, which is not less than 2000. By using the quality analysis method, the separating degree of the Salvianolic acid B chromatographic peaks is improved; the quality analysis can not be interfered by other components; the method has high repeatability and is simple and accurate; and the quality of the Zhongfenghuichun capsules can be effectively controlled.
57. 101843884 Method for testing quality of antiviral oral liquid for treating hand-foot-and-mouth disease
CN
29.09.2010
G01N 30/02 Loading...
G01N 30/02
Loading...
201010183008.8
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Cai Chunling
G01N 30/02
Loading...
The invention discloses a method for testing the quality of antiviral oral liquid for treating the hand-foot-and-mouth disease and relates to the technical field of medicaments. In the method for testing the quality, the quality is tested by using a high performance liquid chromatogram single-test multi-evaluation method. 10 ml of antiviral oral liquid contains no less than 60 mu g of (R,S)-goitrin, no less than 1 mg of forsythoside A, no less than 0.25 mg of forsythin and no less than 0.12 mg of forsythingenin. The method has the advantages that: the method is simple and convenient; the content of four active ingredients of the antiviral oral liquid can be tested at the same time; the quality of the antiviral oral liquid and the curative effect of the antiviral oral liquid on the hand-foot-and-mouth disease can be comprehensively evaluated by establishing a quantitative analysis result of the active ingredients of the antiviral oral liquid, so the antiviral oral liquid has a truly-controllable standard; and simultaneously, the medicinal material basis of a Chinese medicinal preparation, namely, the antiviral oral liquid in the aspect of curing the hand-foot-and-mouth disease is put forward in China for the first time.
58. 101683387 Medication and preparation method and application thereof
CN
31.03.2010
A61K 36/537 Loading...
A61K 36/537
Loading...
200810223440.8
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Luo Guoan
A61K 36/537
Loading...
The present invention discloses a medication and a preparation method and application thereof Active components of the medication are ginseng extract and salvia miltiorrhiza extract; a weight ratio between the ginseng extract and the salvia miltiorrhiza extract is 1:(0.1-20); a weight percentage content of total ginsenoside in the ginseng extract is larger than 50%; and a weight percentage contentof salvianolic acid in the salvia miltiorrhiza extract is larger than 50%. As shown in the result of Wistar rat myocardial infarction experiment and myocardial ischemia experiment, the reconstitutionof total ginsenoside and salvianolic acid has an optimal therapeutic effect, can effectively control Wistar rat myocardial infarction area and improve myocardial ischemia situation, furthermore, hasa same therapeutic effect with an original medicinal material reconstitution prescription. Pharmaceutical ingredient of the medication of the invention is clear and the quality of the medication can be controlled easily.
59. 101143154 Method for preparing surface cladding super-micro traditional Chinese medicine material crude slice
CN
19.03.2008
A61K 9/28 Loading...
A61K 9/28
Loading...
200710041332.4
Hu Ping
Wang Yiming
A61K 9/28
Loading...
The invention discloses a preparation method of a decoction piece of superfine traditional Chinese medicine, the surface of which is coated, including the steps of processing, coarse crushing, superfine crushing, tablet forming and granulizing. When the step of the superfine crushing is executed, a surface coating agent is synchronously introduced, and the surface coating agent forms a protective layer at the surface of the traditional Chinese medicine. The method of the invention can retain the effective components of the raw materials of the traditional Chinese medicine and improve the fluidity of the superfine traditional Chinese medicine powder during the processes of traditional Chinese medicine crushing, tablet forming and storing. The decoction piece of superfine traditional Chinese medicine, which is prepared by the invention, can be conveniently used; the dissolution is fast; the biological utilization degree is high; the batch production can be realized.
60. 1939525 Production of antiviral oral liquid
CN
04.04.2007
A61K 9/08 Loading...
A61K 9/08
Loading...
200610122442.9
Xiangxue Pharmaceutical Co., Ltd., Guangzhou
Lian Linsheng
A61K 9/08
Loading...
An improved process for preparing the antiviral oral liquid with high content of volatile oil includes such steps as oil-water separation of the calpis containing volatile oil, including the volatile oil by water-soluble cyclodextrin to obtain included substance, mixing it with auxiliary, and filtering.
61. 1939524 Method for controlling antiviral oral liquid
CN
04.04.2007
G01N 30/02 Loading...
G01N 30/02
Loading...
200610122441.4
Xiangxue Pharmaceutical Co., Ltd., Guangzhou
Lian Linsheng
G01N 30/02
Loading...
A quaility control method for the antiviral oral liquid features that on the basis of existing quality control standards, the gas-phase chromatography method is additionally used to measure the content for patchoulic alcohol to ensure that it is not less than 10 micrograms per 10 ml.
62. 1679799 Chinese medicine slices and preparation thereof
CN
12.10.2005
A61K 35/78 Loading...
A61K 35/78
Loading...
200510032777.7
Xiangxue Pharmaceutical Co., Ltd., Guangzhou City
Song Lifei
A61K 35/78
Loading...
A novel form of raw Chinese-medicinal materials is prepared from the raw Chinese-medicinal materials or the traditional pieces of Chinese-medicinal material through pulverizing and die pressing to obtain particles or tablets or filling in capsules. Its advantages are high metering accuracy, high utilization rate, and standardized production.
63. 1583084 Use of anti-virus oral liquid
CN
23.02.2005
A61P 27/02 Loading...
A61P 27/02
Loading...
200410027315.1
Xiangxue Pharmaceutical Co., Ltd., Guangzhou City
Tong Xin
A61P 27/02
Loading...
An application of the antiviral oral liquid is preparing the medicines for treating conjunctivitis, especially the acute conjunctivitis, is disclosed.
64. 1538170 Finger print atlas detection technique for antivirus oral liquid
CN
20.10.2004
G01N 30/88 Loading...
G01N 30/88
Loading...
03140112.0
Guangzhou Xiangxue Pharmaceutical Co., ltd.
Song Lejei
G01N 30/88
Loading...
A fingerprint atlas method for testing the antivirus oral liquid, a Chinese medicine, includes such steps as using ether to extract from specimen, dissolving the residue by hexane to obtain the test liquid for gas-phase chromatography, dissolving the evaporated hexane residue to obtain the test liquid for liquid-phase chromatography, obtaining the gas-phase and liquid-phase chromatographic fingerprint atlas of extract, and comparing them with the reference to determine the property of the medicine.
65. 2584552 一种固体药品或食品的包装盒
CN
05.11.2003
B65D 75/34 Loading...
B65D 75/34
Loading...
02272140.1
广州市香雪制药股份有限公司
王永辉
B65D 75/34
Loading...
一种固体药品或食品的包装盒，涉及固体药品或食品的包装结构、形状及其结合的改进。它是将药品或食品被包裹在铝塑薄膜压合的铝塑片3的泡罩4中，而两片的铝塑片的结构、形状、大小相同，并能互相扣合，再将扣合后的铝塑片置于外盒中，外盒的形状与铝塑片3的形状相同。用了本实用新型所说的包装盒，使外包装的体积减少，在包装盒上又有新颖性和实用性，对生产厂商具有一定的有益效果。

